Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Stephan EstermannDavid Goldblum

Abstract

Donepezil, a selective acetylcholinesterase (AChE) inhibitor, has been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbit eyes. The aim of this investigation was to evaluate the effect of oral donepezil on IOP and pupil diameter after mid-term oral treatment in normotensive persons. Thirty-two newly diagnosed Alzheimer patients with normal IOP and no further antiglaucomatous treatment were included in the study. IOP and pupil diameter were evaluated before and 4 weeks after daily intake of 5 mg donepezil. IOP and pupil diameter were significantly lower/smaller after 4 weeks of treatment. The mean IOP of all 63 eyes was 14.1 mmHg before and 12.8 mmHg after treatment (8.8% reduction). Mean pupil diameter constricted from 3.9 to 3.6 mm (-7.4%). These findings show that donepezil, and, possibly, other selective AChE inhibitors, can potentially be used to treat glaucoma. They are also known to have neuroprotective effects in Alzheimer's, and, therefore, might have an additional therapeutic benefit.

References

Feb 1, 1991·Archives of Ophthalmology·C S TsaiF Y Hsieh
Jul 17, 1991·JAMA : the Journal of the American Medical Association·J M TielschJ Javitt
Jan 1, 1990·Ophthalmology·A A Sadun, C J Bassi
Sep 1, 1989·British Journal of Pharmacology·A J HunterA R Green
Nov 6, 1989·Brain Research·J C BlanksC A Miller
Jul 1, 1988·British Journal of Clinical Pharmacology·Q A Mekki, P Turner
Aug 21, 1986·The New England Journal of Medicine·D R HintonC A Miller
Apr 1, 1967·The British Journal of Ophthalmology·C I PhillipsD J Rowlands
Jan 1, 1982·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·E Stenkula, K Wettrell
May 1, 1996·American Journal of Ophthalmology·R F Brubaker
May 1, 1996·The British Journal of Ophthalmology·H A Quigley
Jul 1, 1996·Drugs & Aging·B Fulton, P Benfield
May 1, 1997·Australian and New Zealand Journal of Ophthalmology·J C Vickers
Dec 5, 1998·British Journal of Clinical Pharmacology·S L RogersL T Friedhoff
Jan 19, 2000·Current Medicinal Chemistry·H SugimotoY Kawakami
Feb 15, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·D GoldblumM Böhnke
Mar 21, 2001·Methods and Findings in Experimental and Clinical Pharmacology·H OguraY Yamanishi
Mar 27, 2002·European Neurology·A U BayerC Erb
May 8, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yuki TakadaAkinori Akaike
May 29, 2003·Current Drug Targets. CNS and Neurological Disorders·M J O'NeillS Duty
Sep 6, 2003·Frontiers in Bioscience : a Journal and Virtual Library·Stuart J McKinnon
Apr 28, 2004·Investigative Ophthalmology & Visual Science·Erica WehrweinCindy L Linn

❮ Previous
Next ❯

Citations

Jul 9, 2013·Cell Biochemistry and Biophysics·Jing-bo LiJia-hua Fang
Aug 7, 2014·Neurodegenerative Disease Management·Mohammad H DehabadiM Francesca Cordeiro
May 12, 2011·Neuromolecular Medicine·Alexandra AbramssonHenrik Zetterberg
Dec 17, 2009·Optometry : Journal of the American Optometric Association·Denise A Valenti
Jul 16, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Mark W AlbersLi I Zhang
Oct 5, 2017·American Journal of Alzheimer's Disease and Other Dementias·Vinod KaushikMukaila A Raji

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.